Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective cohort study of rivaroxaban for heparin-induced thrombocytopenia
MOH_2017-09-11_000804Phase 4Not yet recruiting
- Sponsor
- ד"ר גליה ספקטר
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rivaroxaban in heparin-induced thrombocytopenia (HIT), sponsored by ד"ר גליה ספקטר. Planned start Jun 2017; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
heparin-induced thrombocytopenia (HIT)
Beyond the preview
Go deeper on MOH_2017-09-11_000804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-09-11_000804.